Stem definition | Drug id | CAS RN |
---|---|---|
tranquillizers, neuroleptics, 4'-fluoro-4-piperidinobutyrophenone derivatives | 1677 | 3575-80-2 |
Molecule | Description |
---|---|
Synonyms:
|
|
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
0.30 | g | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 21.70 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 14 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 46 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1972 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Systemic infection | 85.93 | 44.18 | 18 | 1235 | 2265 | 50601606 |
Sleep-related eating disorder | 78.52 | 44.18 | 14 | 1239 | 754 | 50603117 |
Peripheral circulatory failure | 62.46 | 44.18 | 11 | 1242 | 551 | 50603320 |
Syncope | 51.84 | 44.18 | 32 | 1221 | 102970 | 50500901 |
General physical health deterioration | 51.59 | 44.18 | 36 | 1217 | 142398 | 50461473 |
Epilepsy | 45.98 | 44.18 | 18 | 1235 | 21549 | 50582322 |
Haematemesis | 44.91 | 44.18 | 19 | 1234 | 27706 | 50576165 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Fall | 94.50 | 45.73 | 67 | 1072 | 177111 | 29396277 |
General physical health deterioration | 66.61 | 45.73 | 44 | 1095 | 102813 | 29470575 |
Pleurothotonus | 56.56 | 45.73 | 12 | 1127 | 1026 | 29572362 |
Disorientation | 53.66 | 45.73 | 25 | 1114 | 29490 | 29543898 |
Gastrointestinal hypermotility | 51.11 | 45.73 | 8 | 1131 | 121 | 29573267 |
Electrocardiogram QT shortened | 49.95 | 45.73 | 8 | 1131 | 141 | 29573247 |
Fracture | 47.79 | 45.73 | 15 | 1124 | 6038 | 29567350 |
Epilepsy | 47.64 | 45.73 | 20 | 1119 | 18412 | 29554976 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
General physical health deterioration | 118.87 | 39.20 | 79 | 2184 | 204346 | 64292123 |
Fall | 110.48 | 39.20 | 101 | 2162 | 416725 | 64079744 |
Pleurothotonus | 79.47 | 39.20 | 18 | 2245 | 2284 | 64494185 |
Systemic infection | 68.21 | 39.20 | 18 | 2245 | 4303 | 64492166 |
Disorientation | 56.76 | 39.20 | 31 | 2232 | 55797 | 64440672 |
Sleep-related eating disorder | 56.49 | 39.20 | 11 | 2252 | 671 | 64495798 |
Peripheral circulatory failure | 56.34 | 39.20 | 11 | 2252 | 680 | 64495789 |
Epilepsy | 55.80 | 39.20 | 26 | 2237 | 33505 | 64462964 |
Drug interaction | 51.15 | 39.20 | 63 | 2200 | 362020 | 64134449 |
Depressed level of consciousness | 43.56 | 39.20 | 30 | 2233 | 81406 | 64415063 |
Syncope | 41.00 | 39.20 | 38 | 2225 | 157597 | 64338872 |
None
Source | Code | Description |
---|---|---|
ATC | N05AD03 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Butyrophenone derivatives |
None
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.28 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | Ki | 6.98 | WOMBAT-PK | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.82 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | WOMBAT-PK | |||||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.66 | PDSP | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.72 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.68 | PDSP | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 6.74 | WOMBAT-PK | |||||
D(3) dopamine receptor | GPCR | Ki | 7.06 | WOMBAT-PK | |||||
Histamine H1 receptor | GPCR | Ki | 6.24 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.62 | PDSP | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.36 | PDSP | |||||
5-hydroxytryptamine receptor 1D | GPCR | Ki | 5.47 | PDSP | |||||
Cytochrome P450 2D6 | Enzyme | WOMBAT-PK | |||||||
D(4) dopamine receptor | GPCR | Ki | 6.39 | WOMBAT-PK |
ID | Source |
---|---|
D07309 | KEGG_DRUG |
C0066477 | UMLSCUI |
CHEBI:93626 | CHEBI |
CHEMBL1531134 | ChEMBL_ID |
DB09224 | DRUGBANK_ID |
15387 | PUBCHEM_CID |
2070 | INN_ID |
J8WA3K39B7 | UNII |
29961 | RXNORM |
006742 | NDDF |
441821005 | SNOMEDCT_US |
442519006 | SNOMEDCT_US |
None